$TBPH News

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma Q1 EPS $(0.10) Misses $0.03 Estimate, Sales $17.699M Beat $17.200M Estimate

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Laughing Water Capital’s New Position: Theravance Biopharma (TBPH)

Theravance Biopharma: A Special Situation With A 50-100% Likely Upside

B. Riley Securities Maintains Neutral on Theravance Biopharma, Raises Price Target to $17

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

TD Cowen Maintains Hold on Theravance Biopharma, Raises Price Target to $15

All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy

BTIG Reiterates Buy on Theravance Biopharma, Maintains $21 Price Target

Theravance Bio: Q4 Earnings Snapshot

Theravance Biopharma Q4 EPS $1.15 Beats $1.02 Estimate, Sales $45.891M Miss $50.793M Estimate

Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates

How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash

Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)

Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)

Oppenheimer Downgrades Theravance Biopharma to Perform

Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure